Correlation of HDL Associated Paraoxonase 1 with Oxidative Stress Markers in Hypertensive Dyslipidemic Patients

SUDEEP KUMAR¹, JYOTI BATRA², MANISHA ARORA³

ABSTRACT

Biochemistry Section

Introduction: Paraoxonase 1 (PON 1) is an esterase, exclusively synthesised by the liver and a high density lipoprotein-associated antioxidant enzyme.

Aim: To determine the PON 1 and oxidative stress markers and to find out the possible correlation between them in hypertensive dyslipidemic patients.

Materials and Methods: This study included 500 patients, out of which 250 were diagnosed with hypertension and the remaining 250 were age matched individuals, which serve as controls. PON 1 activity was measured manually by using spectrophotometer, Malondialdehyde (MDA) by TBA method, Superoxide Dismutase (SOD) by Marklund and Marklund, lipid profile was measured by biochemistry auto-analyser.

The statistical differences between cases and controls were

determined by independent student's t-test.

Results: There were significantly increased levels of PON 1, vitamin E and C and SOD in hypertensive subjects as compared to controls. With respect to lipid profile, significantly increased levels of total cholesterol, triglyceride, Low Density Lipoproteins (LDL-c), Very Low Density Lipoprotein (VLDL-c) and decreased level of High Density Lipoproteins (HDL-c) in cases as compared to controls were observed. Moreover, activity of PON 1 was statistically and positively correlated with HDL-c, SOD, vitamin E and C and it negatively correlated with MDA.

Conclusion: It concludes that, in hypertension which is caused due to the interplay of several confounding factors such as oxidative stress, increased oxidised LDL lipoprotein and decrease in the level of antioxidants, the PON 1 activity is found to alter.

Keywords: Antioxidants, Hypertension, Oxidative stress, Triglycerides

INTRODUCTION

Hypertension is a trait opposed to a specific disease and with an ongoing global increase in the incidence. Hypertension is classified into two groups, primary or essential hypertension, and secondary hypertension. Primary hypertension is defined as a rise in blood pressure of unknown cause and secondary is caused by disease of kidney, endocrines or some other organs. An individual with hypertension is at increased risk factor for stroke, heart disease, and kidney failure [1].

Oxidative stress is defined when there is an imbalance between the reactive oxygen species generation and the antioxidant defence system. Increased vascular oxidative stress could be involved in the pathogenesis of hypertension. Lipid peroxidation is a chain reaction initiated by free radicals which provides a continuous supply of other free radicals formed from unsaturated fatty acids which further initiate peroxidation. Malondialdehyde, the end product of lipid per-oxidation can be used as a marker for lipid peroxidation and oxidative stress.

Paraoxonase 1 (PON1), an enzyme which is found exclusively associated with HDL in serum. It protects LDL from oxidation. In humans, PON 1 is an independent, genetic risk factor for coronary artery disease [2,3] and low PON1 activities are observed in atherosclerotic and hypercholesterolemic patients [2,4-6].

An important role is played by PON 1 in the antioxidant system as it is thought to degrade oxidised phospholipids in lipoproteins [7]. In the diseases involving oxidative stress, the circulating PON 1 levels have been found to be altered [8].

There are various studies that point that the oxidative stress is increased in hypertensive patients and it may be caused due to destruction of endothelial cells that are responsible for arterial relaxation. Superoxide anion acts as a vasoconstrictor and is a major determinant of Nitric Oxide (NO) biosynthesis and bioavailability; therefore, it can modify the endothelial cell function. In humans, hypertension is associated with a decrease in NO bioavailability and an increase in oxidative stress [9]. Decreased catalase and/or SOD antioxidant activity along with reduced levels of Reactive Oxygen Species (ROS) scavengers such as glutathione and vitamins C and E also contribute to oxidative stress [10,11].

The study aimed at finding out the concentrations of PON 1 along with oxidative stress markers in hypertensive dyslipidemic patients and ultimately looking for correlation between the two.

MATERIALS AND METHODS

This cross-sectional study was carried out in the Department of Biochemistry, Santosh Medical College and Hospital, Ghaziabad in collaboration with Department of Medicine and Department of Biochemistry, Muzaffarnagar Medical College and Hospital, Muzaffarnagar, after getting approval from ethical committee of Santosh and Muzaffarnagar Medical College and informed consent was taken from all the subjects. The patients were selected from outpatient department of medicine, Muzaffarnagar Medical College, on the basis of inclusion and exclusion criteria. The prevalence rate of hypertension in Muzaffarnagar region was around 20% accordingly, the minimum sample size has been calculated using the appropriate sample size formula:

n=z2pq/d2

Where z=1.96 at 95 % confidence interval,

p=0.20 and q=1-p=0.80,

d=absolute error 5% n= (1.96)2×0.20×0.80/(0.05)2

www.jcdr.net

=245.86≈246

Hence, the minimum sample size for cases=246

Inclusion criteria: Five hundred male subjects were included in this study aged between 30-60 years out of which 250 were hypertensive dyslipidemic and rest 250 were normal healthy controls. Control group included normotensive subjects with a blood pressure of 110-139/60-89 mm Hg while hypertensive case included those with a blood pressure of ≥120/90 mm Hg.

Exclusion criteria: Patients with diabetes, asthma, Chronic Obstructive Pulmonary Disease (COPD), malignancies, Sexually Transmitted Diseases (STDs), cardiac disease, renal diseases, hepatic diseases, myocardial infarction, gout and arthritis were excluded from the study.

Collection of sample: The individuals were requested for overnight fasting. Seven mL of blood samples were drawn with a disposable syringe and collected in a clean, disposable plastic tube from an anterior cubital vein. The serum was separated and lipid profile was done with the fresh sample and rest of the sample was stored at -20°C till analysis.

Parameters Measured

Anthropometric measurement: 1. Anthropometric indices include height and weight. All the individuals were measured wearing light clothing without shoes and hats. Height was measured to the nearest 0.1 cm using a portable stadiometer and weight was measured to the nearest 0.1kg using calibrated platform scales. Body Mass Index (BMI) of the subjects was calculated using standard formula, BMI=Weight (Kg)/{Height (m)}².

2. Blood pressure measurements: Blood pressure was measured with mercury sphygmomanometer using standard recommended procedures.

Biochemical measurement: 1. Paraoxonase 1 activity was measured by the chemical method, by using phenylacetate as substrate [12].

2. Superoxide dismutase activity was measured by the method of Marklund and Marklund [13].

3. Assay of lipid peroxidation (MDA) by Kei Satoh method [14].

4. Vitamin E was estimated by the method of Martinek GR [15] and Vitamin C by the method of Burtis CA [16].

5. Lipid parameters were estimated by the enzymatic method by fully autoanalyser (CPC Turbochem 100).


RESULTS

The mean values of anthropometric parameters of control and hypertensive subjects are depicted in [Table/Fig-1]. [Table/Fig-1] shows that the BMI, Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and WHR (waist-hip circumference ratio) increased significantly in hypertensive subjects as compared to controls. The mean values of lipid parameters (CHO, TG, LDL, and VLDL) PON 1, Vitamin E and C, SOD and MDA are depicted in [Table/Fig-2]. The mean levels of all the lipid parameters except


S. No.	Variants	Hypertensive patients	Healthy Controls	p-value		
1	Age (years)	43.91±7.82	42.48±4.81	0.12		
2	BMI (kg/m²)	27.70±3.19	24.92±3.29	<0.001*		
3	SBP (mmHg)	160.15±6.47	113.86±4.99	<0.001*		
4	DBP (mmHg)	100.15±3.66	81.42±3.82	<0.001*		
5	WHR	0.989±0.049	0.80±0.057	<0.001*		
[Table/Fig-1]: Changes in anthropometric parameters in hypertensive subjects. *p<0.05 considered as statistically significant						

S. No.	Variants	Hypertensive patients	Healthy Control	p-value		
1	Total Cholesterol (mg/dL)	264.30±14.40	197.75±23.21	<0.001*		
2	Triglyceride (mg/ dL)	221.28±35.59	125.93±18.72	<0.001*		
3	VLDL-c (mg/dL)	44.26±7.12	25.19±3.74	<0.001*		
4	HDL-c (mg/dL)	33.70±5.42	48.82±7.68	<0.001*		
5	LDL-c (mg/dL)	186.35±15.78	123.75±21.18	<0.001*		
6	MDA (nmol/mL)	3.73±0.68	2.92±0.46	<0.001*		
7	Vitamin E (mg/ dL)	1.41±0.11	1.76±0.25	<0.001*		
8	Vitamin C (mg/ dL)	1.33±0.133	1.57±0.18	<0.001*		
9	PON 1 (U/mL)	50.95±9.67	67.61±7.45	<0.001*		
10	SOD (U/ml)	8.74±1.29	10.88±1.87	<0.001*		
[Table/Fig-2]: Changes in biochemical parameters in hypertensive subjects. *p<0.05 considered as statistically significant						

HDL and MDA increased significantly whereas HDL, SOD, PON 1 and Vitamin E and C decreased significantly in hypertensive patients as compared to controls.









[Table/Fig-3-7] shows correlation analysis between the studied subjects. Paraoxonase 1 was significantly and positively correlated with HDL-c, SOD, vitamin E and C whereas, it was significantly and negatively correlated with MDA.


DISCUSSION

The present study showed that BMI and WHR were significantly higher in hypertensive subjects as compared to the controls. The hypertensive group had significantly higher fasting cholesterol LDL-c, TG, glucose, and blood pressure levels and decreased



[Table/Fig-5]: Correlation between Paraoxonase 1 and SOD in hypertensive subjects.





levels of HDL-cholesterol as compared to controls. Insulin plays a central role in determining triglyceride clearance from the blood via activation of lipoprotein lipase and triglyceride output through effects on the synthesis and secretion of VLDL by the liver. It is thought that in the insulin-resistant state, triglyceride-rich lipoproteins accumulate in the circulation due to decreased activity of lipoprotein lipase, increased lipolysis in adipose tissue, and increased output of VLDL particles from the liver [17,18]. Our results are in accordance with Saxena T et al., [19] and Choudhury KN et al., [20].

We found a significantly higher level of MDA and significantly decreased levels of SOD, Vitamin E and C, PON 1 in hypertensive patients as compared to healthy controls. The increased oxidative stress levels that we observed in hypertensive patients are consistent with the findings of previous studies [21-23]. The occurrence of oxidative stress may arise from a primary decrease in the antioxidant defence system activity or from an elevation of ROS concentration. This derangement causes oxidative damage to the structure of biomolecules, which involve the antioxidant enzymes, thus, contributing to the oxidative stress found in hypertensives, but not in healthy individuals. As a consequence

of increased ROS, a reduction in the endothelium-dependent vasodilation of the vascular smooth muscle cells of hypertensives could be expected [24,25]. In turn, elevation in blood pressure could also contribute to the increase of ROS, thereby enhancing the mechanism of ROS-mediated hypertension through a complex interdependency.

It was observed by Nakazono K et al., that administration of SOD in hypertensive rats lead to a decrease in the blood pressure while that its administration in normotensive rats does not bring any change in the blood pressure levels suggesting that the SOD eliminates the ROS and relative increase in ROS produces hypertension [26].

Kumar A et al., observed that the activity of PON1 decreases and oxidative stress markers namely MDA and conjugated diene increase in hypertensive subjects [27]. Jena D et al., found the PON 1 activity to be directly proportional to total antioxidant capacity and correlated negatively with total antioxidant load in hypertensive subjects [28].

In the atherosclerotic vascular disease, there is an important role played in the initiation and progression by the increased oxidative stress. Oxidative modification of LDL is inhibited by the PON 1, which is an antioxidant enzyme, and has a contribution in most of the antioxidant activity of HDL. In our observation, PON activity was found to be significantly lowered in the hypertensive subjects than in controls and there is a significant negative correlation between PON1 levels and BMI as well as with MDA level and positive correlations between PON 1 and HDL-cholesterol, antioxidants, namely vitamin E, Vitamin C and SOD.

The present findings demonstrate a correlation between oxidative stress markers and paraoxonase 1 activity. We found a significant and negative correlation between PON 1 and MDA [Table/Fig-4] and the significant positive correlation between PON 1 and HDL-cholesterol [Table/Fig-3], SOD [Table/Fig-5], Vitamin E [Table/Fig-6] and C [Table/Fig-7]. The correlation of PON 1 with oxidative stress-related parameters in hypertensive subjects suggested that these parameters have an additional blood pressure-modulating effect. Essential hypertensive subjects showed an impairment of the antioxidant defence system as assessed by a diminution of plasma antioxidant status and increased oxidants level, is in agreement with previous data [29,30].

LIMITATION

The usefulness of the results of the present study may be limited because we have used only male subjects of 30-60 years age. It is well-known that endogenous and exogenous oestrogens and progestogens, which could be subjected to time-dependent variations in women, are able to modulate renal sodium metabolism as well as the activity of the renin-angiotensin-aldosterone axis [31]. However, future studies are needed in order to get more precise results.

CONCLUSION

Our study concludes that PON 1 activity is decreased and oxidative stress is increased in hypertension. We found a negative correlation between MDA and PON 1 and a positive correlation between PON 1 and HDL-cholesterol, SOD, vitamin E and C. Diet rich in antioxidant, antioxidant therapy and antilipid drugs may also help to raise PON 1 level, thereby reducing morbidity and mortality in hypertensive patients.

REFERENCES

- Oscar AC, Suzanne O. Essential hypertension part I: definition and etiology. Circulation. 2000;3(101):329-35.
- [2] Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD. Paraoxonase 1 (PON1) polymorphisms, haplotypes, and activity in predicting CAD risk in North-West Indian Punjabis. PLoS ONE. 2011;6(5):e17805.
- [3] Agrawal S, Tripathi G, Prajnya R, Sinha N, Gilmour A, Bush L, et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J Med Sci. 2009;63(8):335-44.
- [4] Zhong JK, Gua ZG, Li C, Wang ZK, Lai WY, Tu Y. Probucol alleviates

atherosclerosis and improves high-density lipoprotein function. Lipids Health Dis 2011;10(210):1-9. Available online at 2011, 10:210 http://www.lipidworld.com/ content/10/1/210.

- [5] Camps J, García-Heredia A, Rull A, Alonso-Villaverde C, Aragonès G, Beltrán-Debón R, et al. PPARs in the regulation of paraoxonases; control of oxidative stress and inflammation pathways. PPAR Res.
- [6] Akbas HS, Basyigit S, Suleymanlar I, Kemalogu D, Koc S, Davran F, et al. The assessment of carotid intima-media thickness and serum paraoxonase-1 activity in Helicobacterpyroli positive subjects. Lipids Health Dis. 2010;9(92):1-6. Available online at http://www.lipidworld.com/content/9/1/92.
- [7] Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci. 2009;46(2):83-106.
- [8] Marsillach J, Parra S, Ferré N, Coll B, Alonso-Villaverde C, Joven J, et al. Paraoxonase-1 in chronic liver diseases, neurological diseases, and HIV infection. In: Mackness B, Mackness M, Aviram M, Paragh G, editors. The paraoxonases: their role in disease development and xenobiotic metabolism. Dordrecht: Springer, 2008:187-198.
- [9] Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance? Hypertension. 2004;44(3):248-52.
- [10] Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension. 2003;41(5):1096-101.
- [11] Nasri H, Behradmanesh S, Ahmadi A, Rafieian-Kopaei M. Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients; a randomized, double-blind, placebo-controlled clinical trial. J Nephropathol. 2014;3(1):29-33.
- [12] Lorenz K, Flatter B, Augustine E. Aryl esterase in serum: Elaboration and clinical application of fixed incubation method. Clin Chem. 1979;25(10):1714-20.
- [13] Marklund S, Marklund G. Involvement of superoxide radical in the autoxidation of pyrogallol: a convenient assay for SOD. Eur J Biochem. 1974;16(47):469-74.
- [14] Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta. 1978;90(1):37-43.
- [15] Martinek GR. Method for the Determination of Vitamin E (Total Tocopherols) in Serum.Clinical Chemistry. 1964;10(12):1078-86.
- [16] Burtis CA. and E.R. Ashwood. Tietz Textbook of Clinical Chemistry. 2nd Edn., WB Saunders Co., Philedelphia, U.S.A., Pp: 1275-1512.
- [17] Lewis GF, Steiner G. Acute effect s of insulin in the control of VLDL production in humans. Implications for insulin-resistant state. Diabetes Care.1996;19(4):390-93.

- [18] Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med. 1995;27(4):435-38.
- [19] Saxena T, Naz S. Assessment of HDL Associated- Pon-1 and Lipid Profile In Prehypertensive and Hypertensive Women. Biomed Pharmacol J. 2015;8(2):591-95.
- [20] Choudhury KN, Mainuddin AK, Wahiduzzaman M, Islam SM. Serum lipid profile and its association with hypertension in Bangladesh. Vascular Health and Risk Management. 2014;10:327-32.
- [21] Simic DV, Mimic OJ, Pljesa EM, Savic RA, Opacic M, Matic D, et al. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different Rodrigo et al. Blood Pressure and Oxidative Stress 1167 degrees of essential hypertension. J Hum Hypertens. 2006;20(2):149-55.
- [22] Laffer CL, Bolterman RJ, Romero JC, Elijovich F. Effect of salt on isoprostanes in salt-sensitive essential hypertension. Hypertension. 2006;47(3):434-40.
- [23] Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bächler JP. Relationship between oxidative stress and essential hypertension. Hypertens Res. 2007;30(12):1159-67.
- [24] Lassègue B, Griendling KK. Reactive oxygen species in hypertension. An update. Am J Hypertens 2004;17(9):852-60.
- [25] Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004;122(4):339-52.
- [26] Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA. 1991;88(22):10045-48.
- [27] Kumar A. Correlation of serum paraoxonase activities in known cases of 130 elderly hypertensive south Asian aged 56-64 years - a hospital based study. Asian Pac J Trop Dis. 2014;4(1):931-35.
- [28] Jena D, Devi N, Jena I, Padhy RK, Mishra PK. Study of oxidative stress and serum paraoxonase 1(PON 1) in essential hypertension. Int J Curr Res. 2017;9(3):48004-07.
- [29] Moreno MU, Jose GS, Fortuno A, Beloqui O, Diez J, Zalba G. The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. J Hypertens. 2006;24(7):1299-306.
- [30] Muda P, Kampus P, Zilmer M, Ristimäe T, Fischer K, Zilmer K, et al. Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension. J Hypertens. 2005;23(1):105-12.
- [31] ESHRE Capri Workshop Group: Hormones and cardiovascular health in women. Hum Reprod Update. 2006;12(5):483-97.

PARTICULARS OF CONTRIBUTORS:

- 1. Research Scholar, Department of Biochemistry, Santosh Medical College, Ghaziabad, Uttar Pradesh, India.
- 2. Professor, Department of Biochemistry, Santosh Medical College, Ghaziabad, Uttar Pradesh, India.
- 3. Professor and Head, Department of Biochemistry, Muzaffarnagar Medical College, Muzaffarnagar, Uttar Pradesh, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Sudeep Kumar,

Research Scholar, Department of Biochemistry, Santosh Medical College, Ghaziabad-201009, Uttar Pradesh, India. E-mail: sudeepty@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: May 11, 2018 Date of Peer Review: Jun 07, 2018 Date of Acceptance: Jul 12, 2018 Date of Publishing: Oct 01, 2018